Based on the key indicators related to MacroGenics' liquidity, profitability, solvency, and operating efficiency, MacroGenics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, MacroGenics' Inventory is fairly stable compared to the past year. Deferred Long Term Liabilities is likely to rise to about 71.8 M in 2024, whereas Total Assets are likely to drop slightly above 287.5 M in 2024. Key indicators impacting MacroGenics' financial strength include:
The financial analysis of MacroGenics is a critical element in measuring its lifeblood. Investors should not minimize MacroGenics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(9.51 Million)
MacroGenics
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Change Receivables
Total Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Investments
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Net Tangible Assets
Retained Earnings Total Equity
Short Term Investments
Capital Surpluse
Inventory
Deferred Long Term Liab
Non Current Liabilities Other
Long Term Investments
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Income From Continuing Ops
Non Operating Income Net Other
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past MacroGenics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of MacroGenics' financial statements are interrelated, with each one affecting the others. For example, an increase in MacroGenics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in MacroGenics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MacroGenics. Check MacroGenics' Beneish M Score to see the likelihood of MacroGenics' management manipulating its earnings.
MacroGenics Stock Summary
MacroGenics competes with Molecular Partners, Mineralys Therapeutics,, AN2 Therapeutics, Pharvaris, and PepGen. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 427 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Cash flow analysis captures how much money flows into and out of MacroGenics. It measures of how well MacroGenics is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money MacroGenics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money MacroGenics had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what MacroGenics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining MacroGenics's current stock value. Our valuation model uses many indicators to compare MacroGenics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MacroGenics competition to find correlations between indicators driving MacroGenics's intrinsic value. More Info.
MacroGenics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, MacroGenics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the MacroGenics' earnings, one of the primary drivers of an investment's value.
MacroGenics Systematic Risk
MacroGenics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. MacroGenics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on MacroGenics correlated with the market. If Beta is less than 0 MacroGenics generally moves in the opposite direction as compared to the market. If MacroGenics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one MacroGenics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of MacroGenics is generally in the same direction as the market. If Beta > 1 MacroGenics moves generally in the same direction as, but more than the movement of the benchmark.
MacroGenics Thematic Clasifications
MacroGenics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in MacroGenics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MacroGenics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of MacroGenics growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of MacroGenics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MacroGenics. We use our internally-developed statistical techniques to arrive at the intrinsic value of MacroGenics based on widely used predictive technical indicators. In general, we focus on analyzing MacroGenics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MacroGenics's daily price indicators and compare them against related drivers.
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.